DexCom had five patents in big data during Q4 2023. DexCom Inc has developed a CGM-driven basal insulin titration system for Type 2 Diabetes patients starting on basal insulin therapy. The system uses historical CGM data, insulin dose information, reports of hypoglycemia, and past recommendations to generate adjusted insulin doses and provide guidance on whether to continue titration or stop. Recommendations are generated regularly until an adequate dose size is determined. GlobalData’s report on DexCom gives a 360-degreee view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
DexCom grant share with big data as a theme is 80% in Q4 2023. Grant share is based on the ratio of number of grants to total number of patents.
Recent Patents
Application: System and method for titrating basal insulin doses (Patent ID: US20230338654A1)
The patent filed by DexCom Inc. describes a continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes. The system uses historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations to generate an adjusted insulin dose and provide advice on whether to continue or stop the titration process. The method can generate new recommendations regularly until an adequate, consistent dose size is determined. The system includes modules for receiving and analyzing CGM data, generating daily blood glucose state parameters, modeling dose-response relationships, adjusting target basal insulin doses, and finalizing adjusted doses while adhering to safety rules to prevent hypoglycemia.
The system's claims detail the components and processes involved in the basal titration adjustment device, including the use of various blood glucose state parameters, regularized dose-response models, target dose adjustment, hypoglycemia monitoring, termination checking, and safety rules implementation. The method involves receiving CGM data, generating historical estimated glucose values, analyzing blood glucose state parameters, modeling dose-response relationships, adjusting target basal insulin doses, and finalizing adjusted doses based on safety rules. The patent also covers a non-transitory computer-readable medium containing instructions for performing the method. Overall, the system and method aim to provide personalized and adaptive basal insulin titration for patients with Type 2 Diabetes, enhancing the effectiveness and safety of insulin therapy.
To know more about GlobalData’s detailed insights on DexCom, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
